Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 20S immunoproteasome beta-5i chymotrypsin-like site is the primary catalytic center of the Proteasome subunit beta type-8 (PSMB8), also known as LMP7. This subunit is an inducible component of the immunoproteasome, a specialized variant of the 20S proteasome core particle that is constitutively expressed in hematopoietic cells and upregulated in other tissues by pro-inflammatory cytokines such as interferon-gamma. The beta-5i site possesses chymotrypsin-like activity, which is responsible for cleaving peptide bonds after hydrophobic amino acid residues. This specific proteolytic profile is crucial for generating peptides with high affinity for MHC class I molecules, thereby facilitating the presentation of antigens to CD8+ T cells and driving adaptive immune responses. Pharmacological inhibition of this site is a therapeutic strategy for treating autoimmune and inflammatory diseases, such as systemic lupus erythematosus and rheumatoid arthritis, as well as hematological malignancies like multiple myeloma. Selective inhibitors, such as zetomipzomib (KZR-616) and ONX-0914, are designed to target the immunoproteasome while sparing the constitutive proteasome to reduce systemic toxicities like peripheral neuropathy. However, challenges remain regarding the potential for excessive immunosuppression and the risk of triggering autoinflammatory responses in susceptible individuals.
Inhibition of the chymotrypsin-like catalytic activity of the immunoproteasome beta-5i subunit
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome subunit beta type-8 (PSMB8).